AU2011245384C1 - Formulations of quinones for the treatment of ophthalmic diseases - Google Patents

Formulations of quinones for the treatment of ophthalmic diseases Download PDF

Info

Publication number
AU2011245384C1
AU2011245384C1 AU2011245384A AU2011245384A AU2011245384C1 AU 2011245384 C1 AU2011245384 C1 AU 2011245384C1 AU 2011245384 A AU2011245384 A AU 2011245384A AU 2011245384 A AU2011245384 A AU 2011245384A AU 2011245384 C1 AU2011245384 C1 AU 2011245384C1
Authority
AU
Australia
Prior art keywords
formulation
formula
quinone
mixtures
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011245384A
Other languages
English (en)
Other versions
AU2011245384B9 (en
AU2011245384B2 (en
AU2011245384A1 (en
Inventor
Guy M. Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioelectron Technology Corp
Original Assignee
Edison Phamaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edison Phamaceuticals Inc filed Critical Edison Phamaceuticals Inc
Publication of AU2011245384A1 publication Critical patent/AU2011245384A1/en
Application granted granted Critical
Publication of AU2011245384B2 publication Critical patent/AU2011245384B2/en
Publication of AU2011245384B9 publication Critical patent/AU2011245384B9/en
Publication of AU2011245384C1 publication Critical patent/AU2011245384C1/en
Assigned to BIOELECTRON TECHNOLOGY CORPORATION reassignment BIOELECTRON TECHNOLOGY CORPORATION Request to Amend Deed and Register Assignors: EDISON PHARMACEUTICALS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2011245384A 2010-04-27 2011-04-26 Formulations of quinones for the treatment of ophthalmic diseases Ceased AU2011245384C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32854610P 2010-04-27 2010-04-27
US61/328,546 2010-04-27
US39369310P 2010-10-15 2010-10-15
US61/393,693 2010-10-15
PCT/US2011/033983 WO2011137126A1 (en) 2010-04-27 2011-04-26 Formulations of quinones for the treatment of ophthalmic diseases

Publications (4)

Publication Number Publication Date
AU2011245384A1 AU2011245384A1 (en) 2012-12-06
AU2011245384B2 AU2011245384B2 (en) 2016-02-18
AU2011245384B9 AU2011245384B9 (en) 2016-02-25
AU2011245384C1 true AU2011245384C1 (en) 2016-09-01

Family

ID=44861894

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011245384A Ceased AU2011245384C1 (en) 2010-04-27 2011-04-26 Formulations of quinones for the treatment of ophthalmic diseases

Country Status (13)

Country Link
US (2) US20130109759A1 (enExample)
EP (1) EP2563352A4 (enExample)
JP (2) JP5902673B2 (enExample)
CN (2) CN105147651A (enExample)
AU (1) AU2011245384C1 (enExample)
BR (1) BR112012027543A8 (enExample)
CA (1) CA2797581A1 (enExample)
EA (1) EA201201465A1 (enExample)
MX (1) MX337594B (enExample)
MY (1) MY183449A (enExample)
SG (2) SG10201801321XA (enExample)
WO (1) WO2011137126A1 (enExample)
ZA (1) ZA201208535B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
EA035619B1 (ru) * 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
PL2220030T3 (pl) 2007-11-06 2016-07-29 Bioelectron Tech Corp Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych
EP2237664A4 (en) 2008-01-08 2013-05-22 Edison Pharmaceuticals Inc (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
EP2303824B1 (en) * 2008-06-25 2015-03-25 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
CA2740773A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
WO2010051277A1 (en) 2008-10-28 2010-05-06 Edison Pharmaceuticals, Inc. Process for the production of alpha-tocotrienol and derivatives
CA2777479C (en) 2009-04-28 2017-10-17 Ptc Therapeutics, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
NO2470168T3 (enExample) * 2009-08-26 2018-06-30
EA201201374A1 (ru) * 2010-04-06 2013-04-30 Эдисон Фармасьютикалз, Инк. Лечение атаксии-телеангиэктазии
AU2011245384C1 (en) * 2010-04-27 2016-09-01 Bioelectron Technology Corporation Formulations of quinones for the treatment of ophthalmic diseases
US9464016B2 (en) 2011-06-14 2016-10-11 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
CA2842486C (en) 2011-07-19 2022-09-06 Edison Pharmaceuticals, Inc. Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
CA2883879A1 (en) * 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
JP2016515526A (ja) 2013-03-15 2016-05-30 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
HUE058877T2 (hu) 2014-12-16 2022-09-28 Ptc Therapeutics Inc (R)-2-hidroxi-2-metil-4-(2,4,5-trimetil-3,6-dioxociklohexa-1,4-dienil)butánamid polimorf és amorf alakjai
JP7117241B2 (ja) 2015-12-16 2022-08-12 ピーティーシー セラピューティクス， インコーポレイテッド 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法
EP3389646A1 (en) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
US11260048B2 (en) 2017-10-03 2022-03-01 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
HUE066196T2 (hu) 2018-10-17 2024-07-28 Ptc Therapeutics Inc 2,3,5-trimetil-6-nonilciklohexa-2,5-dién-1,4-dion alfa-szinukleinopátiák, tauopátiák és egyéb rendellenességek szuppresszálására és kezelésére
JP7705106B2 (ja) * 2019-05-28 2025-07-09 ナノ－ネオ リミテッド 網膜症を治療するための組成物及び方法
EP4366700A1 (en) 2021-07-08 2024-05-15 PTC Therapeutics, Inc. Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione
WO2025231245A1 (en) * 2024-05-02 2025-11-06 Stealth Biotherapeutics Inc. Use of substituted 1,4 benzoquinones to treat alpha-synucleinopathies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130775A2 (en) * 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
WO2007100652A2 (en) * 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20100063161A1 (en) * 2008-09-10 2010-03-11 Miller Guy M Treatment of pervasive developmental disorders with redox-active therapeutics
WO2011025785A1 (en) * 2009-08-26 2011-03-03 Edison Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia
WO2011126998A1 (en) * 2010-04-06 2011-10-13 Edison Pharmaceuticals, Inc. Treatment of ataxia telangiectasia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5122460B2 (ja) * 2005-09-16 2013-01-16 アラーガン、インコーポレイテッド 治療薬の眼内輸送のための組成物および方法
AU2011245384C1 (en) * 2010-04-27 2016-09-01 Bioelectron Technology Corporation Formulations of quinones for the treatment of ophthalmic diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130775A2 (en) * 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
WO2007100652A2 (en) * 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20100063161A1 (en) * 2008-09-10 2010-03-11 Miller Guy M Treatment of pervasive developmental disorders with redox-active therapeutics
WO2011025785A1 (en) * 2009-08-26 2011-03-03 Edison Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia
WO2011126998A1 (en) * 2010-04-06 2011-10-13 Edison Pharmaceuticals, Inc. Treatment of ataxia telangiectasia

Also Published As

Publication number Publication date
JP6266674B2 (ja) 2018-01-24
EA201201465A1 (ru) 2013-04-30
SG10201801321XA (en) 2018-04-27
BR112012027543A2 (pt) 2019-05-28
CN105147651A (zh) 2015-12-16
EP2563352A1 (en) 2013-03-06
BR112012027543A8 (pt) 2019-12-03
JP2013525443A (ja) 2013-06-20
US20130109759A1 (en) 2013-05-02
JP2016106144A (ja) 2016-06-16
AU2011245384B2 (en) 2016-02-18
CA2797581A1 (en) 2011-11-03
CN102985083A (zh) 2013-03-20
WO2011137126A1 (en) 2011-11-03
US20170354618A1 (en) 2017-12-14
MX337594B (es) 2016-03-11
JP5902673B2 (ja) 2016-04-13
ZA201208535B (en) 2016-06-29
MX2012012518A (es) 2012-12-17
MY183449A (en) 2021-02-18
AU2011245384A1 (en) 2012-12-06
EP2563352A4 (en) 2013-11-13
SG185046A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
AU2011245384B2 (en) Formulations of quinones for the treatment of ophthalmic diseases
AU2011245384B9 (en) Formulations of quinones for the treatment of ophthalmic diseases
US20100273892A1 (en) Formulations of tocotrienol quinones for the treatment of ophthalmic diseases
CA2777479C (en) Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
US20120136048A1 (en) Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
JP2019034979A (ja) 眼部における摩擦を低減させるための組合せの使用、及び眼科組成物の製造方法
HK1168028B (en) Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
HK1168028A (en) Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones

Legal Events

Date Code Title Description
SREP Specification republished
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 MAY 2016 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 MAY 2016

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: BIOELECTRON TECHNOLOGY CORPORATION

Free format text: FORMER NAME(S): EDISON PHARMACEUTICALS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired